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ABSTRACT
Loss-of-function by means of RNA interference in
cultured human cells enables rapid pathway dis-
section on a genome-scale. Improved siRNA design
and key validation protocols are required to elim-
inate falsely identified phenotypes resulting from
potential off-target consequences. Here, we demon-
strate a validation strategy involving several steps
for verifying cell death phenotypes revealed during
loss-of-function screening. First, from a set of 45
novel human genes we identified gene candidates
that, when silenced, induce apoptosis in cultured
HeLa cells. For those candidates, we performed
more extensive validation with multiple effective
siRNAs.Inaddition,wedesignedrescueexperiments
involving candidate genes delivered exogenously
and containing silent mutations in the siRNA target
regions. Rescue of the observed knockdown pheno-
type demonstrated an original and more stringent
validation of the siRNA’s selectivity and the pheno-
type specificity for the target gene. As a result, our
data reveals an anti-apoptotic function for novel
human breast adenocarcinoma marker BC-2, adding
new depth to BC-20s description as a putative
tumor marker involved in cancer related pathways.
INTRODUCTION
Rapid gene silencing through RNA interference (RNAi)
has accelerated the genome-wide study of gene function
with unparalleled speed by offering a simpler alternative to
previously established reverse genetic approaches. Large-
scale RNAi has facilitated the search for genes required for
diverse biological processes enabling stepwise dissection of
speciﬁc signaling pathways. Recently, large-scale RNAi
in the form of short interfering RNAs (siRNA) has been
successfully employed in human cell lines to screen for
regulators of TRAIL-induced apoptosis (1), to link speciﬁc
kinase subfamilies involved in regulating clathrin-mediated
endocytosis (2) and to identify genes essential for cell
division (3).
However, reports that siRNAs may induce ‘off-target’ ﬂuc-
tuations in the expression of genes not related to their cognate
mRNAs (4–6) have generated skepticism over the speciﬁcity
of siRNA in mammalian cells. The somewhat limited speci-
ﬁcity implied by off-target results emphasizes not only the
need for careful siRNA design but also the critical inter-
pretation with which RNAi-derived phenotypes must be
regarded. Phenotypic observations generated by speciﬁc siR-
NAs designed according to the most stringent guidelines must
be conﬁrmed experimentally by channeling data through a
series of key validation steps. In this report, we performed
RNAi in human HeLa cells targeting a set of novel genes in
medium-scale assays screening for phenotypes inﬂuencing
cell viability and speciﬁcally apoptosis. In addition, we inclu-
ded a combination of validation steps that allowed us to identi-
fy with conﬁdence among our collection a new anti-apoptotic
protein essential for cell viability.
MATERIALS AND METHODS
Gene cloning, oligonucleotide templates for siRNAs
Detailed methods for cloning the novel genes included in the
present study have been described previously (7,8). The 21 nt
cDNA templates used for siRNA production were designed
using Ambion siRNA-ﬁnding software, according to the cri-
teria described previously (9). These siRNA templates are
compatible for use with the Silencer  siRNA Construction
Kit (Ambion). In the preliminary siRNA design, three cDNA
templates for siRNA production were selected for each gene
and were generated according to the manufacturer’s recom-
mendations. Following the preliminary cell proliferation and
apoptosis screening assays, gene candidates were selected for
which a second effective siRNA was generated by the method
described above. The ﬁrst and second siRNAs were tranfected
in parallel in order to compare gene knockdown efﬁciency.
siRNA templates are shown in Supplementary Table 2. Sense
and antisense templates were synthesized by Thermo Electron
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doi:10.1093/nar/gnj015GmbH. A non-speciﬁc siRNA was included as negative
control (Dharmacon Inc).
Cell culture and siRNA transfection
Cultured HeLa cells were transfected with plasmid DNA or
siRNA as described (10) with some modiﬁcations. Brieﬂy,
human HeLa cells were maintained in DMEM medium sup-
plemented with 10% fetal bovine serum, penicillin (100 U/ml)
and streptomycin (100 mg/ml). Cells were passed regularly
to maintain robust growth. Before 24 h of transfection, cells
were trypsinized, collected and diluted with fresh medium
either with or without antibiotics depending on whether
transfections were performed with HiPerFECT (Qiagen) or
Lipofectamine 2000 (Invitrogen), respectively. Initial trans-
fections for identifying effective siRNAs were carried out
in 24-well cell culture plates, while cell apoptosis assays
were carried out in 96-well cell culture microplates
(COSTAR3603, CORNING). Each sample was assayed
in triplicate. siRNAs were used at a ﬁnal concentration of
20 nM in all experiments.
Generation of point mutations
For rescue experiments, mutations were generated using
the QuikChange II Site-Directed Mutagenesis Kit
(STRATAGENE), according to the manufacturer’s protocol.
To fully abolish the siRNA effect, two nucleic acids in the
siRNA-targeted regions were mutated.
Immunofluorescence microscopy
Cell ﬁxation and immunostaining were performed according
to previously described methods (7). Cells were stained with
rabbit anti-cleaved Caspase 3 (Cell Signaling Technology)
diluted 1:100 subsequently detected with donkey anti-rabbit
conjugated with Cy3 diluted 1:1200 (Jackson Laboratories).
Cell apoptosis assays
Caspase-3/7 activities were measured using the Apo-ONE
Homogeneous Caspase-3/7 Assay kit (Promega) according
to the manufacturer’s protocol. HeLa cells were plated in
triplicate in 96-well cell culture plates (COSTAR3603,
CORNING). After 48 h siRNA transfection, cells were
lysed with lysis buffer containing caspase substrate Z-
DEVD-R100, and incubated at room temperature until
being analyzed. Assays were measured by detection with a
ﬂuorescence microplate reader (LABVISION system,
BMG Labtechnologies), and the ﬂuorescence was measured
at an excitation/emission wavelength of 485/535 nm. Results
are presented as the mean ± the standard deviation of the
triplicates.
Western blotting, RNA isolation and RT–PCR analysis
Total RNA from siRNA transfected cell lines was prepared
according to the methods described previously (8). Gene
knockdown efﬁciency by the speciﬁc siRNAs was assessed
both from protein levels by western blot and from mRNA
levels by RT–PCR for every gene in our collection according
to methods also described previously (8).
RESULTS AND DISCUSSION
The objectives of our study were to explore loss-of-function
for a set of novel human genes using RNAi in cultured
HeLa cells and to establish an efﬁcient and reliable validation
strategy for identifying anti-apoptotic proteins. The 45 human
genes reported here (Supplementary Table 1) were selected on
the basis of previously described criteria for the purpose of
employing various cell-based screening methods for gaining
insight into function (7,8). Brieﬂy, the selected human genes
encode proteins for which little or no functional data is
available as determined by limited descriptions from public
resources such as NCBI; hence they are referred to as novel.
Additionally, the genes share at least one common domain
between several eukaryotic genomes, including ﬂy and
worm, a property that denotes a conserved function.
Loss-of-function screening identifies candidates
influencing caspase activity
In order to gain a basic insight into the function of the novel
genes, we ﬁrst aimed to identify genes that inﬂuence cell
viability by carryingout assays measuring apoptosis. Effective
siRNAs for each gene were identiﬁed according to previously
described methods (8). siRNA efﬁciency was evaluated from
both the transcript level of the target gene and the correspond-
ing protein level of an exogenously added gene product. Only
the siRNAs that are able to effectively reduce expression of
both the corresponding mRNAs and the ectopically expressed
gene products were considered for our functional assays
(Supplementary Table 2, Supplementary Figure 1). HeLa
cells were then transfected with the selected 45 siRNAs in
96-well plates and assays were performed using the Apo-ONE
Homogeneous Caspase-3/7 Assay (Promega) monitoring the
activation of caspases 3 and 7, indicators of apoptosis, by
ﬂuorescence detection. We observed that siRNA-mediated
inactivation of two candidate genes (RefSeq Accession nos
NM_014453 and NM_025238 or genes BC-2 and BTBD1
isoform 1, respectively) triggered a signiﬁcant increase in
caspase 3/7 activity within 48 h of siRNA transfection
(Figure 1A).
Importantly, recent reports have demonstrated a possible
risk for siRNA-induced off-target consequences (4–6).
These observations have challenged the idea that siRNAs
are able to induce silencing exclusively for their target
gene. That is to say, the cognate gene function may have little
to do with the observed phenotype. It has been suggested
that some off-target effects arise from unintended sequence
homology with other transcripts containing as few as 15 or less
contiguous bases in common. Therefore, if using only one
siRNA per gene, the reliability of any observed phenotype
would be questionable and difﬁcult to interpret, a factor
that strongly compelled us to pursue a secondary selection
of effective siRNAs for the identiﬁed candidates. Additional
siRNAs selected against BC-2 and BTBD1 demonstrated
RNA and protein silencing efﬁciency comparable to that of
the ﬁrst siRNAs tested when transfected into HeLa cells in
parallel (Figure 1B). In order to validate the phenotypic hits,
we repeated the Apo-ONE Homogeneous Caspase-3/7 Assay
with both effective siRNAs identiﬁed for the two candidate
genes (Table 1). BC-2 reduction by the second siRNA strongly
activated caspase 3/7 in HeLa cells (Figure 2E), a ﬁnding that
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the phenotypicconsequence ofthegene targeting experiments.
However, the second siRNA targeting BTBD1 did not induce
equivalent levels of caspase 3/7 activity in HeLa cells
compared to the ﬁrst siRNA, suggesting that the initially
chosen BTBD1 siRNA gave rise to an off-target or toxic effect
not linked to the function of this gene (Supplementary
Figure 2C).
Downstream assays support caspase activation as a
consequence of BC-2 reduction
In order to conﬁrm the ﬁndings obtained by the Apo-ONE
assay, we performed additional experiments monitoring the
effects of BC-2 inactivation. Immunoﬂuorescence microscopy
with an antibody against cleaved-caspase 3, the active form of
the protein, reiterated the Apo-ONE assay results showing a
marked increase in detection of this marker in cells transfected
with the two separate siRNAs against BC-2 (Figure 2A).
Activation of apoptosis was also conﬁrmed by western
blot with an antibody against poly-ADP-ribose polymerase
(PARP) which is cleaved downstream of caspase 3 at a
later stage of apoptosis (Figure 2B).
Induction of apoptosis through loss of BC-2 can
be rescued
Rescue experiments represent a more stringent way in which
the selectivity and the speciﬁcity of siRNA knockdown may
be veriﬁed. This strategy is particularly interesting both from
the pharmaceutical point of view where, for many genes, the
RNAi-knockdown can only be measured from enzymatic or
metabolic activity, and especially for addressing those genes
for which only one siRNA is available.
Figure 1. Activationof caspase3 characterizessiRNA-induced cell apoptosis.(A) HeLa cells were transfected in parallelwith 45 gene-specific siRNAsand a non-
specific controlsiRNA.Refseq andGenBanknucleotideaccession numbersare indicated foreach gene. Errorbarsrepresentthe standarddeviationof meanvalues.
Twocandidategeneswereisolatedforfurthervalidationstudies(indicated byarrows).TwoeffectivesiRNAsweredesignedforeach candidateand theirefficiency
was evaluated in two ways. (B) First, exogenous levels of 3xFLAG fusion proteins expressing the genes of interest were monitored in co-transfection experiments
with corresponding siRNAs. Fusion protein levels were detected by anti-FLAG. Second, endogenous gene levels of the targeted mRNA by RT–PCR.
Table 1. Candidate genes identified and corresponding siRNA target sequences
Refseq accession nos Symbol Description siRNA 1 siRNA 2
NM_014453 BC-2 Putative breast adenocarcinmarker AAGGCCAGATGGATGCTGTTC AAGGAGGAGATGATGAATGAT
NM_025238 BTBD1 BTB (POZ) domain containing Isoform 1 AAAGTAGTGCATGAGACACCT AATAGATTCCAGCAAGTAGAA
Control siRNA DNA template AACAGTCGCGTTTGCGACTGG
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the BC-2 gene and the speciﬁcity of the phenotype, we per-
formed a rescue experiment employing two expression con-
structs containing the entire coding region of the BC-2 gene
fused to an N-terminal 3xFLAG sequence. The two constructs,
one for each siRNA, were designed to contain silent point
mutations by substituting the third base position of two codons
each within the respective regions targeted by the two siRNAs
(Figure 2C). We demonstrate that the two point mutations are
sufﬁcient to fully abolish any siRNA knockdown of the
expression level of the mutant BC-2 protein, further indicating
that the siRNAs are highly selective for the endogenous BC-2
gene (Figure 2D). We further demonstrate that both of the
exogenous BC-2 mutant constructs successfully rescued
HeLa cells from apoptosis when co-transfected with the cor-
responding siRNAs, suggesting that this phenotype is directly
linked to an anti-apoptotic BC-2 function (Figure 2E). Rescue
experiments were repeated using a plasmid containing the
wild-type BC-2 gene (BC-2 wt). As expected, wild-type
BC-2 does not rescue apoptotic cell-death induced by the
BC-2 siRNAs, as expression of the non-mutated protein,
both endogenous and overexpressed, is successfully abrogated
Figure 2. BC-2 reduction promotes apoptosis.BC-2 siRNA-induced apoptosis was detected by immunofluorescence in HeLa cells stained with rabbit anti-cleaved
Caspase 3 (A). PARP cleavage was also detected by western blot using anti-PARP (B). Two different 3xFLAG-tagged BC-2 mutants (BC-2mut1 and BC-2mut2)
were generatedby site-directed mutagenesis with two silent pointmutationseach corresponding to siRNAtargetedregions (C). In parallel,plasmids containingthe
original 3xFLAG-tagged BC-2 or the mutated versions were co-transfected into HeLa cells with siRNA1, siRNA2 or with control siRNA. Point mutations fully
abolished siRNA effects on the exogenous BC-2 fusion protein (D). Rescue experiments were performed by co-transfection with BC-2 siRNAs (siRNA1 and
siRNA2)andaplasmidconstructexpressingeitherthemutated3xFLAG-taggedBC-2(BC-2mut1andBC-2mut2)(E)orthe3xFLAG-taggedwild-typeBC-2(BC-
2wt)(F).After48 h,theculturedcells wereassayedforCaspase3/7activity.Errorbarsrepresentthestandarddeviationofmean values.ThemutatedBC-2proteins
prevent cells from BC-2 siRNA-induced apoptosis (E). BC-2wt does not rescue siRNA-induced cell death (F).
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tion of effective siRNAs for our novel genes, we observed that
as little as 1 nM siRNA could sufﬁciently silence exogenously
overexpressed genes. By performing the rescue experiments
forbotheffective siRNAs, wedeterminedthatthe activationof
caspase 3 was speciﬁcally elicited by loss of the BC-2 gene.
Furthermore, the discriminate silencing of the non-mutated
BC-2, but not the mutated BC-2, supports the idea that
siRNA signaling requires near perfect homology with the
target transcript.
The putative breast adenocarcinoma 2 gene is also descri-
bed as CHMP2A or chromatin modifying protein 2A; charged
multivesicular body forming protein 2A and contains an
ESCRT-III domain that is associated with endosome to lyso-
some protein sorting and transport. However, it is clear that
BC-20s function may lie beyond that which has been described
for members of the ESCRT-III complex (11). Interestingly,
BC-20s closest relative among the CHMP family of proteins,
CHMP1, has been reported to be a nuclear matrix protein
possibly involved in gene silencing and cell cycle progression
(12). Based on our previous ﬁnding that overexpressed BC-2
localizes to the nucleus both diffusely and in discrete foci (13),
BC-2 may participate in nuclear events leading to transcrip-
tional repression of genes necessary for apoptosis. The dis-
covery of this new anti-apoptotic protein may be of particular
importance considering that the aberrant expression of such
proteins has been shown to contribute to tumor development.
The mis-regulation of anti-apoptotic genes can confer resist-
ance to cell death programs normally executed in response to
stress, DNA damage or insults to proper chromosome segrega-
tion (14). This ability to avert death directly contributes
to cancer progression. The identiﬁcation of anti-apoptotic
genes, such as BC-2 will provide new candidates for cancer
therapies (15).
siRNA induced apoptosis cannot be rescued by BTBD1
Although both siRNAs directed against BTBD1 showed com-
parable silencing efﬁciency (Figure 1B), the two siRNAs did
not induce similar levels of caspase activity (Supplementary
Figure 2C). Because of the discrepancy between the two
BTBD1 siRNAs in the level of caspase activity induced,
we sought further validation of this phenotype by employing
rescue experiments similar to those performed for BC-2
(Supplementary Figure 2). Expressing the BTBD1mut1 con-
struct did not prevent the HeLa cell apoptosis induced by the
initial BTBD1 siRNA, suggesting that this siRNA induces an
off-target or toxic effect. In this case, the rescue experiment
was a necessary additional measure for resolving the conﬂict-
ing results provided by two independent siRNAs against
BTBD1.
Concluding remarks
In conjunction with our aim to dissect function for our genes
of interest, we have demonstrated a series of essential steps
toward the validation of siRNA-induced phenotypic hits. Fur-
thermore, the validation strategy introduced here has enabled
the identiﬁcation of a novel anti-apoptotic gene that may
uncover an important link in mechanisms leading to cancer
development.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
The authors are grateful to Jenny Redelius for helping with the
immunofluorescence microscope. This work was supported by
grants from Karolinska Institute, the Swedish Cancer Society
and the Swedish Research Council. Funding to pay the Open
Access publication charges for this article was provided by
Swedish Cancer Society.
Conflict of interest statement. None declared.
REFERENCES
1. Aza-Blanc,P., Cooper,C.L., Wagner,K., Batalov,S., Deveraux,Q.L. and
Cooke,M.P. (2003) Identification of modulators of TRAIL-induced
apoptosis via RNAi-based phenotypic screening. Mol. Cell, 12,
627–637.
2. Pelkmans,L.,Fava,E.,Grabner,H.,Hannus,M.,Habermann,B.,Krausz,E.
and Zerial,M. (2005) Genome-wide analysis of human kinases in
clathrin- and caveolae/raft-mediated endocytosis. Nature, 436,
78–86.
3. Kittler,R., Putz,G., Pelletier,L., Poser,I., Heninger,A.K., Drechsel,D.,
Fischer,S.,Konstantinova,I., Habermann,B., Grabner,H.et al.(2004) An
endoribonuclease-preparedsiRNAscreeninhumancellsidentifiesgenes
essential for cell division. Nature, 432, 1036–1040.
4. Jackson,A.L., Bartz,S.R., Schelter,J., Kobayashi,S.V., Burchard,J.,
Mao,M., Li,B., Cavet,G. and Linsley,P.S. (2003) Expression profiling
reveals off-target gene regulation by RNAi. Nat Biotechnol., 21,
635–637.
5. Scacheri,P.C., Rozenblatt-Rosen,O., Caplen,N.J., Wolfsberg,T.G.,
Umayam,L., Lee,J.C., Hughes,C.M., Shanmugam,K.S.,
Bhattacharjee,A., Meyerson,M. et al. (2004) Short interfering RNAs can
induce unexpected and divergent changes in the levels of untargeted
proteins in mammalian cells. Proc. Natl Acad. Sci. USA, 101,
1892–1897.
6. Snove,O.,Jr and Holen,T. (2004) Many commonly used siRNAs risk
off-target activity. Biochem. Biophys. Res. Commun., 319, 256–263.
7. Hodges,E., Redelius,J., Wu,W. and Hoog,C. (2005) Accelerated
discovery of novel protein function in cultured human cells. Mol. Cell.
Proteomics, 4, 1319–1327.
8. Wu,W.,Hodges,E.,Redelius,J.andHoog,C.(2004)Anovelapproachfor
evaluating the efficiency of siRNAs on protein levels in cultured cells.
Nucleic Acids Res., 32, e17.
9. Elbashir,S.M., Harborth,J., Lendeckel,W., Yalcin,A., Weber,K. and
Tuschl,T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA
interference in cultured mammalian cells. Nature, 411, 494–498.
10. Elbashir,S.M., Harborth,J., Weber,K. and Tuschl,T. (2002) Analysis of
gene function in somatic mammalian cells using small interfering
RNAs. Methods, 26, 199–213.
11. Babst,M., Katzmann,D.J., Estepa-Sabal,E.J., Meerloo,T. and Emr,S.D.
(2002) Escrt-III: an endosome-associated heterooligomeric protein
complex required for mvb sorting. Dev. Cell, 3, 271–282.
12. Stauffer,D.R., Howard,T.L., Nyun,T. and Hollenberg,S.M. (2001)
CHMP1 is a novel nuclear matrix protein affecting chromatin structure
and cell-cycle progression. J. Cell Sci., 114, 2383–2393.
13. Hodges,E., Redelius,J.S., Wu,W. and Hoog,C. (2005) Accelerated
discovery of novel protein function in cultured human cells. Mol. Cell.
Proteomics, 4, 1319–1327.
14. Gleave,M.E.andMonia,B.P.(2005)Antisensetherapyforcancer.Nature
Rev. Cancer, 5, 468–479.
15. Igney,F.H. and Krammer,P.H. (2002) Death and anti-death: tumour
resistance to apoptosis. Nature Rev. Cancer, 2, 277–288.
PAGE 5 OF 5 Nucleic Acids Research, 2006, Vol. 34, No. 2 e13